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We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET mono-
therapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY 
study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c] ≥7.0% 
at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups 
were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% com-
pared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in 
MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated 
with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently im-
proved the long-term glycaemic durability as compared with MET. 
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INTRODUCTION
Diabetes is a global epidemic with 60% of the affected popula-
tion living in Asian countries [1]. In 2016, approximately 5.02 
million adults were diagnosed with type 2 diabetes mellitus 
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as approximately 8.7 million people have been diagnosed with 
impaired fasting glucose [2] and a quarter of these individuals 
have a high likelihood of developing T2DM over a period of 3 
to 5 years [3].
As per the Korean Diabetes Association (KDA), 43.1% of all 
diagnosed patients with T2DM were reported to be untreated 
[2]. Among those undergoing treatment, 75% patients fail to 
achieve the KDA recommended glycosylated hemoglobin 
(HbA1c) target of <6.5% with current standard-of-care [2].
Although international guidelines recommend initial mono-
therapy for treatment of T2DM [4], studies have showed that 
treatment with initial combination of dipeptidyl peptidase 4 
inhibitors (DPP4i) with metformin resulted in significant 
HbA1c reductions compared with a traditional stepwise ap-
proach [5].
The recent Vildagliptin Efficacy in combination with met-
foRmIn For earlY treatment of type 2 diabetes (VERIFY) trial 
demonstrated that early intervention strategy with a combina-
tion therapy of vildagliptin (DPP4i) plus metformin in treat-
ment-naïve patients with T2DM provides greater and more 
durable long-term clinical benefits compared with the current 
standard-of-care metformin monotherapy [6]. 
The aim of this regional analysis from the VERIFY study is 
to elucidate the clinical benefits of an early intervention ap-
proach in patients with newly diagnosed T2DM from Korea.
METHODS
Study design and patients 
VERIFY was a Phase IV, randomized, double-blind, parallel-
group study involving patients (18 to 70 years) with T2DM 
(HbA1c, 6.5% to 7.5%) across 34 countries. Early combination 
(EC) treatment included metformin (stable daily dose of 1,000, 
1,500, or 2,000 mg) and vildagliptin 50 mg twice daily, or stan-
dard-of-care initial metformin monotherapy and placebo 
twice daily (Supplementary Fig. 1). The detailed study design 
has been published previously [7]. 
The VERIFY study enrollment period was from March 30, 
2012 to April 10, 2014. The last trial visit was on April, 2019. 
The study was performed in accordance with the ethical princi-
ples laid down in the Declaration of Helsinki and was registered 
with ClinicalTrials.gov (NCT01528254). The results for the 
VERIFY study have been posted on ClinicalTrials.gov and EU 
Clinical Trials Register (www.clinicaltrialsregister.eu). This 
study was approved by the Institutional Review Board of Catho-
lic Medical Center, College of Medicine, The Catholic Universi-
ty of Korea (IRB no. F1-06-2). Written informed consent was 
obtained from all patients.
Assessments
The primary efficacy endpoint was the time to confirmed ini-
tial treatment failure, defined as HbA1c ≥7.0% at two consec-
utive planned post-randomization visits, 13 weeks apart. Sec-
ondary endpoints were time to second treatment failure (two 
consecutive values of HbA1c ≥7.0% when all patients were re-
ceiving combination therapy); change in HbA1c (%) from 
baseline; and safety and tolerability. Adverse events (AEs) and 
serious AEs were recorded, with their severity and relationship 
to study drug over the entire study duration. The detailed sta-
tistical analysis of the VERIFY study was published earlier [8]. 
A P value of 0.05 (2-sided) was considered significant. The sta-
tistics program used was SAS versions 9.2 and 9.4 (SAS Insti-
tute Inc., Cary, NC, USA).
RESULTS
A total of 39 eligible patients were randomized to receive either 
EC (n=22) or initial metformin monotherapy (n=17) and the 
majority (n=28, 71.8%) completed the 5-year study. The over-
all median (interquartile range [IQR]) age for Korean patients 
was 53.5 years (IQR, 46.0 to 59.0) with 48.7% being females 
with a mean±standard deviation body mass index (BMI) of 
26.3±2.6 kg/m2. Median duration of T2DM was 3.2 months 
(IQR, 0.8 to 8.0) in the EC group and 1.7 months (IQR, 0.1 to 
9.0) in the monotherapy group. The other baseline demo-
graphics and clinical characteristics were similar between the 
two treatment groups (Supplementary Table 1). 
At the end of the study, 15% (n=3) of the patients in EC 
group versus 58.8% (n=10) in the monotherapy group at-
tained the primary end-point (P=0.0228). The median ob-
served time to treatment failure in the monotherapy group was 
45.7 months (IQR, 26.6 to 59.9) compared with 58.5 months 
(IQR, 30.1 to 60.0) for those receiving EC. These three patients 
in the EC group with initial treatment failure later attained gly-
caemic control (HbA1c <7%) without insulin treatment. In 
the EC group, no patient experienced secondary treatment 
failure compared to five patients (29.4%) in the metformin 
monotherapy group (Fig. 1). Similar benefits with EC was 
shown across baseline subgroups (Supplementary Fig. 2). 
Compared to metformin monotherapy a greater proportion 
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of patients with EC presented with HbA1c cut-off values 
<7.0%, <6.5%, and <6.0% over 5 years (Supplementary Fig. 
3). Overall the pattern of HbA1c reduction in the EC group 
had a characteristic rapid and sustained decline immediately 
after randomization (Fig. 2). Glycaemic control and long-term 
durability was better with EC than the initial monotherapy 
(Fig. 2) even if the analysis of coefficient of failure does not ap-
ply to the study design with protocol-defined rescue therapy 
implementation (vs. intention-to-treat). 
No hypoglycaemic events were reported in Korean patients 
and no AE led to treatment discontinuation. Both treatment 
approaches were well tolerated with no new safety findings 
(Supplementary Table 2). 
DISCUSSION
This regional analysis of the VERIFY study has shown that EC 
with vildagliptin plus metformin improved glycaemic durabil-
ity in Korean patients with newly diagnosed T2DM compared 
with standard-of-care initial metformin monotherapy fol-
lowed by sequential combination with vildagliptin. Implemen-
tation of EC treatment strategy significantly reduced the risk of 
time to initial treatment failure among Korean participants by 
78% compared to the metformin monotherapy throughout the 
5-year study duration. 
A recent Korean study reported that only 25% of patients 
with T2DM receiving standard-of-care achieved the treatment 
Fig. 1. Time to treatment failure. (A) Cumulative probability of initial treatment failure. (B) Cumulative probability of second treat-
ment failure. The Kaplan-Meier (KM) estimates were performed for patients who had received at least one randomized medication 
and one post-randomization efficacy parameter assessed. Thus, not all patients included in the KM analysis had data at month 0. 
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goal of HbA1c <6.5% in clinical practice [2], whereas 85% of 
Korean patients achieved long-term glycaemic control with EC 
in this regional analysis. Furthermore, the lack of secondary 
loss of glycaemic control among those few failing on EC sup-
ports the overall conceptual success and claims of long-term 
durability with this rather novel combination therapy ap-
Fig. 2. (A) Glycosylated hemoglobin (HbA1c) levels over 12 months by treatment approaches and (B) long-term glycaemic dura-
bility in patients without treatment failure in both treatment groups (those remaining in Period 1). (A) Early combination: This 
group includes all patients who started treatment with vildagliptin plus metformin. Initial monotherapy: This group includes all 
patients who started treatment with metformin plus placebo. The analysis was performed for patients who had received at least 
one randomized medication and one post-randomization efficacy parameter assessed. (B) Patients failing on initial monotherapy: 
These patients received combination therapy after initial treatment failure with metformin monotherapy. Patients not failing on 
initial monotherapy: These patients continued with metformin monotherapy till the end of the study. Patients failing on early 
combination: These patients continued to receive combination therapy until secondary treatment failure. Patients not failing on 
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proach. A rapid reduction of HbA1c with EC within the first 3 
months was observed along with well-maintained long-term 
glycaemic durability. This suggests that lowering HbA1c 
around 6.0% with EC might be recommended for manage-
ment of newly diagnosed patients with T2DM. These clinical 
observations led to the expected, rather recent updates in the 
position statement from the American Diabetic Association 
and European Association for the Study of Diabetes mention-
ing that healthcare providers should engage in shared decision 
making around initial combination therapy in new-onset cases 
of T2DM [9].
This regional analysis also demonstrated long-term glycae-
mic control with EC without any hypoglycaemic events despite 
sustained attainment of low HbA1c levels. This can be attribut-
ed to vildagliptin which leads to improved, glucose-dependent 
response by both α- and β-pancreatic cells, which in turn con-
tributes to its low hypoglycaemic potential [10].
Diabetes pathophysiology and management requirements in 
the Asian population differ from that of Western population. 
Early insulin secretion failure, rather than insulin resistance 
plays a primary role in development of T2DM in the Asian 
population [11-14]. Also, diabetes in the Asian population is 
characterised by a younger age and lower BMI [15-17], which 
is reflected in this analysis of Korean patients with T2DM 
when compared to the global VERIFY population (Supple-
mentary Table 3) [18].
The results of this regional analysis should be extrapolated 
with caution due to the small sample size, narrow HbA1c cut-
off (6.5% to 7.5%) at baseline and the assessment of only one 
treatment combination. Other studies addressing individual-
ised EC for all the possible permutations of the recommended 
oral therapeutic alternatives must follow for solving the ques-
tions regarding the generalisability of the VERIFY study re-
sults.
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